NDM-Producing Multidrug-Resistant Klebsiella pneumoniae in a Secondary-Level Hospital: A Critical Threshold in a Resource-Limited Setting

Autores/as

DOI:

https://doi.org/10.69639/arandu.v13i1.2073

Palabras clave:

multidrug-resistant Klebsiella pneumoniae, intensive care unit, bronchoalveolar lavage, NDM, resource-limited setting

Resumen

This case report describes the clinical course of a 52-year-old patient with multiple comorbidities admitted to the intensive care unit due to acute respiratory distress. Despite initial supportive management, the patient developed progressive clinical deterioration during a prolonged ICU stay, with subsequent suspicion of a healthcare-associated lower respiratory tract infection. After 21 days of hospitalization, bronchoscopy with bronchoalveolar lavage was performed, and microbiological culture identified multidrug-resistant Klebsiella pneumoniae. In a resource-limited setting, the diagnostic process was further supported by privately funded multiplex testing arranged by the patient’s relatives, which helped clarify the microbiological profile and reinforced therapeutic decision-making. This case illustrates the complex interaction between critical illness, prolonged ICU exposure, invasive procedures, and the emergence of highly resistant pathogens, including NDM-associated resistance patterns, in secondary-level hospitals with limited diagnostic capacity. It also highlights the clinical value of bronchoscopy and bronchoalveolar lavage in targeted etiological assessment when conventional approaches are insufficient. The case underscores the growing threat posed by multidrug-resistant gram-negative infections in critical care and the urgent need to strengthen local microbiological support, antimicrobial stewardship, and early diagnostic strategies in resource-constrained institutions.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Braun, H. G., Perera, S. R., Tremblay, Y. D., & Thomassin, J.-L. (2024). Antimicrobial resistance in Klebsiella pneumoniae: An overview of common mechanisms and a current Canadian perspective. Canadian Journal of Microbiology, 70(12), 507–528. https://doi.org/10.1139/cjm-2024-0032

Miller, W. R., & Arias, C. A. (2024). ESKAPE pathogens: Antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nature Reviews Microbiology, 22(10), 598–616. https://doi.org/10.1038/s41579-024-01054-w

Wyres, K. L., Lam, M. M. C., & Holt, K. E. (2020). Population genomics of Klebsiella pneumoniae. Nature Reviews Microbiology, 18(6), 344–359. https://doi.org/10.1038/s41579-019-0315-1

Wyres, K. L., & Holt, K. E. (2018). Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. Current Opinion in Microbiology, 45, 131–139. https://doi.org/10.1016/j.mib.2018.04.004

Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015). Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrobial Agents and Chemotherapy, 59(10), 5873–5884. https://doi.org/10.1128/AAC.01019-15

Howroyd, F., Chacko, C., MacDuff, A., et al. (2024). Ventilator-associated pneumonia: Pathobiological heterogeneity and diagnostic challenges. Nature Communications, 15(1), 6447. https://doi.org/10.1038/s41467-024-50805-z

Torres, A., Niederman, M. S., Chastre, J., et al. (2017). International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 50(3), Article 1700582. https://doi.org/10.1183/13993003.00582-2017

Martin-Loeches, I., Torres, A., Nagavci, B., et al. (2023). ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Medicine, 49(6), 615–632. https://doi.org/10.1007/s00134-023-07033-8

Darie, A. M., Khanna, N., Jahn, K., et al. (2022). Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): A multicentre, randomised controlled trial. The Lancet Respiratory Medicine, 10(9), 877–887. https://doi.org/10.1016/S2213-2600(22)00086-8

Pickens, C. I., & Wunderink, R. G. (2022). Clinical impact of bacterial syndromic testing in pneumonia. The Lancet Respiratory Medicine, 10(9), 816–818. https://doi.org/10.1016/S2213-2600(22)00095-9

Salina, A., Schumann, D. M., Franchetti, L., Jahn, K., Purkabiri, K., Müller, R., et al. (2022). Multiplex bacterial PCR in the bronchoalveolar lavage fluid of non-intubated patients with suspected pulmonary infection: A quasi-experimental study. ERJ Open Research, 8(2), Article 00595-2021. https://doi.org/10.1183/23120541.00595-2021

Chen, C.-L., Tseng, H.-Y., Chen, W.-C., et al. (2024). Application of a multiplex molecular pneumonia panel and real-world impact on antimicrobial stewardship among patients with hospital-acquired and ventilator-associated pneumonia in intensive care units. Journal of Microbiology, Immunology and Infection, 57(3), 480–489.

Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clinical Infectious Diseases, ciae403. https://doi.org/10.1093/cid/ciae403

Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., et al. (2022). European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clinical Microbiology and Infection, 28(4), 521–547. https://doi.org/10.1016/j.cmi.2021.11.025

Jesudason, T. (2024). WHO publishes updated list of bacterial priority pathogens. The Lancet Microbe, 5(9), Article 100940. https://doi.org/10.1016/j.lanmic.2024.07.003

Sati, H., Carrara, E., Savoldi, A., Hansen, P., Garlasco, J., Campagnaro, E., et al. (2025). The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet Infectious Diseases, 25(9), 1033–1043.

Soria-Segarra, C., Soria-Segarra, C., Molina-Matute, M., Agreda-Orellana, I., Núñez-Quezada, T., Cevallos-Apolo, K., et al. (2024). Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador. BMC Infectious Diseases, 24(1), Article 378. https://doi.org/10.1186/s12879-024-09248-6

Heng, H., Yang, X., Ye, L., Tang, Y., Guo, Z., Li, J., Chan, E. W.-C., Zhang, R., & Chen, S. (2024). Global genomic profiling of Klebsiella pneumoniae: A spatio-temporal population structure analysis. International Journal of Antimicrobial Agents, 63(2), Article 107055. https://doi.org/10.1016/j.ijantimicag.2023.107055

Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025). Multidrug-resistant Gram-negative bacterial infections. The Lancet, 405(10474), 257–272. https://doi.org/10.1016/S0140-6736(24)02081-6

Russo, T. A., & Marr, C. M. (2019). Hypervirulent Klebsiella pneumoniae. Clinical Microbiology Reviews, 32(3), e00001-19. https://doi.org/10.1128/CMR.00001-19

Descargas

Publicado

2026-04-06

Cómo citar

Córdova Loor , F. J., Henríquez Acosta, N. L., Arguello Sánchez, C. A., & López Silva , K. M. (2026). NDM-Producing Multidrug-Resistant Klebsiella pneumoniae in a Secondary-Level Hospital: A Critical Threshold in a Resource-Limited Setting. Arandu UTIC, 13(1), 2620–2638. https://doi.org/10.69639/arandu.v13i1.2073

Número

Sección

Psicología y Ciencias de la Salud

Artículos similares

<< < 5 6 7 8 9 10 11 12 13 14 > >> 

También puede Iniciar una búsqueda de similitud avanzada para este artículo.

Artículos más leídos del mismo autor/a